Tiagabine in glial tumors
Related Experiment Video
Updated: Oct 1, 2026
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Salvatore Striano1, Pasquale Striano, Patrizia Boccella
1Department of Neurological Sciences, Epilepsy Center, "Federico II" University, Naples, Italy. sstriano@libero.it
Rationale And Purpose:
Preliminary reports have suggested a possible 'aetiology-specific' efficacy of tiagabine (TGB) in patients with drug-resistant partial epilepsy (DRPE) related to cerebral glial tumors (GTs). This efficacy should be related to selective blocking of GAT-1 transporter by TGB. We presented our open-label, add-on TGB experience in a group of patients with GTs, compared with other symptomatic DRPEs of different aetiology.
Material And Methods:
eleven patients with DRPE related to oligodendroglioma (six cases), astrocytoma (4) or multiform gliobastoma (1); 12 patients with DRPE related to a miscellanea of CNS lesions. TGB was added to previous AEDs, at dosage of 20-60 mg per die. Responders are defined by seizure frequency reduction >50% compared with baseline.
Results:
Seven patients are responders with three seizure-free (SF) in GTs group, a rate of efficacy much higher than in matching group (63.6 vs. 16.6%). Adverse events have been observed only rarely, not leading to discontinuation, in GTs group.
Conclusion:
This preliminary observation seems to confirm the high efficacy and tolerability of TGB in DRPE related to GTs.
More Related Videos
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:15Drugs that Stabilize Microtubules